OncoMatch/Clinical Trials/NCT06537843
Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia
Is NCT06537843 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Venetoclax and Cytarabine for acute myeloid leukemia.
Treatment: Venetoclax · Cytarabine · Metformin — Phase 2 clinical trial to evaluate the combination of venetoclax, cytarabine and metformin in relapsed-refractory and induction ineligible acute myeloid leukemia.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 2–3(Limited self-care)
Lab requirements
Kidney function
creatinine clearance below 60 mL/min/1,73m²
Cardiac function
left ventricular ejection fraction ≤ 50%
creatinine clearance below 60 mL/min/1,73m², left ventricular ejection fraction ≤ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify